| Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies (NCT05206045) | Assistance Publique - Hôpitaux de Paris | 2022-01-01 |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat (NCT04955340) | 4SC AG | 2021-10-12 |
| Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome (NCT04960618) | Memorial Sloan Kettering Cancer Center | 2021-10-01 |
| Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides (NCT04676087) | Emory University | 2021-04-21 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment (NCT04541017) | National Cancer Institute (NCI) | 2021-04-06 |
| Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. (NCT04904146) | Lund University Hospital | 2021-04-02 |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (NCT04312841) | Ohio State University Comprehensive Cancer Center | 2020-09-15 |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome (NCT04256018) | Stanford University | 2020-03-30 |
| Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome (NCT04185220) | National Cancer Institute (NCI) | 2020-02-26 |
| Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides (NCT03695471) | Mayo Clinic | 2020-02-04 |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies (NCT03905135) | National Cancer Institute (NCI) | 2019-06-07 |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas (NCT03373305) | City of Hope Medical Center | 2019-03-01 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (NCT03602157) | UNC Lineberger Comprehensive Cancer Center | 2018-10-29 |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients (NCT03587844) | Memorial Sloan Kettering Cancer Center | 2018-07-03 |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma (NCT02341209) | Rochester General Hospital | 2018-02-06 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625) | National Cancer Institute (NCI) | 2017-09-27 |
| Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma (NCT03011814) | City of Hope Medical Center | 2017-03-08 |
| Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL (NCT02811783) | Elorac, Inc. | 2017-01-01 |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (NCT02953301) | 4SC AG | 2016-11-01 |
| AEDV Registry of Primary Cutaneous Lymphoma (NCT03646422) | Fundación Academia Española de Dermatología | 2016-09-01 |
| Tissue Repository: CTCL Collection Protocol (NCT02840747) | Columbia University | 2016-07-01 |
| VircapSeq Virus Detection in Sézary Syndrome (NCT02836886) | Columbia University | 2016-06-01 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) (NCT02542124) | Neumedicines Inc. | 2015-12-01 |
| Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome (NCT01625455) | Vanderbilt University Medical Center | 2012-02-01 |
| Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level (NCT01396070) | Youn Kim | 2011-05-01 |
| Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma (NCT00896493) | Stanford University | 2009-05-01 |
| Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma (NCT00748319) | Assistance Publique - Hôpitaux de Paris | 2009-03-01 |
| A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) (NCT00611208) | Virogen Biotechnology Inc. | 2008-01-01 |
| Effect of Denileukin Diftitox on Immune System in CTCL Patients (NCT00254332) | University of Pittsburgh | 2005-11-01 |
| Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome (NCT00157274) | Latin American Cooperative Onco-Haematology Group - Peru | 2005-07-01 |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome (NCT00127881) | Emergent Product Development Seattle LLC | 2005-07-01 |
| Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL (NCT00178841) | Vanderbilt University | 2005-06-01 |
| Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) (NCT00091559) | Merck Sharp & Dohme LLC | 2005-02-03 |
| Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research (NCT00177268) | University of Pittsburgh | 2004-10-01 |
| Immunization Against Tumor Cells in Sezary Syndrome (NCT00099593) | University of Pittsburgh | 2004-09-01 |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome (NCT00047060) | National Heart, Lung, and Blood Institute (NHLBI) | 2002-07-30 |
| In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) (NCT00177190) | University of Pittsburgh | 2002-06-01 |
| Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients (NCT00050999) | Eisai Inc. | 1995-06-01 |